{"id":"beta-ergocryptine","rwe":[],"tags":[{"label":"beta-Ergocryptine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"beta ergocryptine","offLabel":[],"synonyms":["beta-Ergocryptine","beta ergocryptine","beta-Ergokryptine"],"timeline":[],"brandName":"Beta Ergocryptine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"beta-Ergocryptine","explanation":"Imagine your brain is a complex orchestra, and dopamine is the conductor that helps different parts work together. Beta Ergocryptine is thought to affect the way dopamine conducts the orchestra, which can influence various bodily functions. However, the exact details of how it interacts with dopamine receptors are not yet fully understood.","oneSentence":"Beta Ergocryptine is believed to work by interacting with dopamine receptors in the brain.","technicalDetail":"Beta Ergocryptine is a dopamine receptor agonist, which means it binds to and activates dopamine receptors in the brain, potentially influencing various physiological processes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ergocryptine","title":"Ergocryptine","extract":"Ergocryptine is an ergopeptine and one of the ergoline alkaloids. It is isolated from ergot or fermentation broth and it serves as starting material for the production of bromocriptine. Two isomers of ergocryptine exist, α-ergocryptine and β-ergocryptine. The beta differs from the alpha form only in the position of a single methyl group, which is a consequence of the biosynthesis in which the proteinogenic amino acid leucine is replaced by isoleucine. β-Ergocryptine was first identified in 1967 by Albert Hofmann. Ergot from different sources have different ratios of the two isomers."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3183","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=beta-Ergocryptine","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Ergocryptine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:00:03.936199","biosimilars":[],"competitors":[],"genericName":"beta-ergocryptine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"61KMR73K97","PUBCHEM_CID":"15586930"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Beta Ergocryptine, a small molecule drug, is a member of the beta-Ergocryptine class. Its exact target and mechanism of action are unknown, but it is believed to work by interacting with dopamine receptors in the brain. Beta Ergocryptine is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and approved indications are currently unavailable.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}